Skyrizi Kit
NDC Package 0074-1065-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Skyrizi (risankizumab-rzaa) kits is a medication used to treat plaque psoriasis. This formulation utilizes a kit delivery system. Marketed by Abbvie Inc., this product is identified by NDC 0074-1065 and is authorized under FDA application BLA761105.

Identification & Billing

NDC Package Code
0074-1065-01
Package Description
1 KIT in 1 CARTON * 1.2 mL in 1 CARTRIDGE (0074-1066-02) * 1.2 mL in 1 CARTRIDGE (0074-1066-01)
Product Code
0074-1065
11-Digit Billing Format
00074106501
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 2166136 - risankizumab-rzaa 75 MG in 0.83 mL Prefilled Syringe
  • RxCUI: 2166136 - 0.83 ML risankizumab-rzaa 90.4 MG/ML Prefilled Syringe
  • RxCUI: 2166136 - risankizumab-rzaa 75 MG per 0.83 ML Prefilled Syringe
  • RxCUI: 2166137 - {2 (0.83 ML risankizumab-rzaa 90.4 MG/ML Prefilled Syringe) } Pack
  • RxCUI: 2166137 - risankizumab-rzaa 75 MG in 0.83 mL (2) Prefilled Syringe Pack

Clinical Specifications

Proprietary Name
Skyrizi
Non-Proprietary Name
Risankizumab-rzaa
Dosage Form
Kit - A packaged collection of related material.
Administration Route
Intravenous - Administration within or into a vein or veins.
Usage Information
This medication is used to treat plaque psoriasis. Risankizumab-rzaa belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural protein in your body (interleukin-23) that may cause inflammation and swelling.

Regulatory & Marketing

Labeler Name
Abbvie Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA761105
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
09-23-2022
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0074-1065). Click a package code to view its specific billing and regulatory data.

0074-1065-02
1 KIT in 1 CARTON * 1.2 mL in 1 CARTRIDGE (0074-1066-02) * 1.2 mL in 1 CARTRIDGE (0074-1066-01)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0074-1065-01 identifies a specific commercial package of 1 kit in 1 carton * 1.2 ml in 1 cartridge (0074-1066-02) * 1.2 ml in 1 cartridge (0074-1066-01) of Skyrizi, a human prescription drug labeled by Abbvie Inc.. This kit is formulated for intravenous use and contains as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Abbvie Inc. on September 23, 2022. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to treat plaque psoriasis. Risankizumab-rzaa belongs to a class of drugs known as monoclonal antibodies. It works by blocking a certain natural protein in your body (interleukin-23) that may cause inflammation and swelling.

How is this Abbvie Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00074106501. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0074-1065-01
11-Digit CMS (5-4-2)
00074-1065-01

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.